Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000525369 | SCV000644779 | uncertain significance | Atrial septal defect 7 | 2021-09-21 | criteria provided, single submitter | clinical testing | Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on NKX2-5 function (PMID: 15917268). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 9011). This missense change has been observed to co-occur in individuals with a different variant in NKX2-5 that has been determined to be pathogenic (PMID: 15161646), but the significance of this finding is unclear. This missense change has been observed in individuals with Tetralogy of Fallot and ventricular septal defects (PMID: 11714651, 15161646). This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with valine at codon 219 of the NKX2-5 protein (p.Ala219Val). The alanine residue is highly conserved and there is a small physicochemical difference between alanine and valine. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002362574 | SCV002664807 | uncertain significance | Cardiovascular phenotype | 2019-02-21 | criteria provided, single submitter | clinical testing | The p.A219V variant (also known as c.656C>T), located in coding exon 2 of the NKX2-5 gene, results from a C to T substitution at nucleotide position 656. The alanine at codon 219 is replaced by valine, an amino acid with similar properties. This variant has been detected in a proband with tetralogy of Fallot and an in an unaffected parent (Goldmuntz E et al. Circulation, 2001 Nov;104:2565-8). This variant has also been detected in probands with ventricular septal defect; however, some cases also had an additional NKX2-5 variant (Reamon-Buettner SM et al. Am. J. Pathol., 2004 Jun;164:2117-25). A yeast assay reported this variant may have mild impact on function (Inga A et al. Hum. Mol. Genet., 2005 Jul;14:1965-75). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002482847 | SCV002785915 | uncertain significance | Atrial septal defect 7; Conotruncal heart malformations; Hypothyroidism, congenital, nongoitrous, 5; Tetralogy of Fallot; Ventricular septal defect 3; Hypoplastic left heart syndrome 2 | 2021-10-12 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000009576 | SCV000029794 | pathogenic | Tetralogy of Fallot | 2005-07-15 | no assertion criteria provided | literature only |